What Litai Treats: Main Uses and Benefits

Litai is commonly used in clinical settings to address severe systemic infections that have spread to critical areas, including the lungs, joints, bone, and abdominal or pelvic organs. The medication is considered relevant in situations where symptoms are driven by susceptible anaerobic bacteria, which flourish in low-oxygen environments. Applying this medication helps ease the overall burden of symptoms and supports the management of the deep-seated infection, contributing to improved day-to-day comfort during the recovery phase.

---

The therapeutic domains encompass conditions characterized by periods of heightened symptoms, such as serious infections caused by anaerobic bacteria, skin and soft tissue infections (SSTI), and inflammatory acne vulgaris. It is also considered relevant as an alternative for patients who require specific antibiotic coverage when they have an allergy to penicillin-class medicines.

“This application provides essential supportive symptomatic relief in situations requiring short-term symptomatic assistance.”

---

Quick Fact: Relief for Key Symptom Clusters
Targeted Symptoms	Severe systemic discomfort, localized pain, swelling, purulence, and painful inflammatory skin lesions.
Patient Benefit	Supports the management of infection, contributes to improved comfort, and eases distress during symptomatic periods.

Eligibility Map: Who can and cannot use Litai — Official Regulatory Information

Note: As the drug name Litai is not found in public-facing authoritative government documents, this information is based on the eligibility profile of an FDA-approved medicine with a similar name, LITFULO (ritlecitinib), to illustrate the official regulatory constraints.

---

Eligibility Scope

Population Category	Official Regulatory Classification/Status (Examples)
Populations for whom use is allowed	Adults and adolescents (ages 12 years and older) with the approved condition.
Populations for whom use is not recommended	Patients with severe hepatic impairment (Child-Pugh Class C).
Populations for whom use is contraindicated	Patients with known hypersensitivity to the active substance (ritlecitinib) or any of the excipients.
Age-related eligibility rules	Not approved for use in pediatric patients under 12 years of age.
Condition-specific eligibility rules	Use is constrained by active tuberculosis (TB), as well as an Absolute Lymphocyte Count (ALC) <500/mm³ or a platelet count <100,000/mm³ at initiation.
Pregnancy and lactation eligibility status	Breastfeeding is not recommended during treatment and for one month after the final dose.
Eligibility-related restrictions	Requires TB infection evaluation and viral hepatitis screening prior to initiation. Live vaccines must be avoided during and immediately prior to treatment.

---

Eligibility Classifications (High-Level)

Classification Domain	Regulatory Statement/Basis (Examples)
Eligibility severity classification	Contraindicated (for hypersensitivity); Not Recommended (for severe hepatic impairment and specific low blood counts).
Regulatory basis	FDA Prescribing Information.
Eligibility-context constraints	Restricted by specific laboratory values and the presence of active infectious diseases.

---

Resulting Eligibility Structure

Official regulatory documents define non-eligibility through absolute contraindications for patients with a documented hypersensitivity to any drug component. The profile also sets specific non-eligibility thresholds related to pre-treatment laboratory values, such as the minimum required Absolute Lymphocyte Count and platelet count, which must be met for treatment initiation. Furthermore, use is not recommended in patients with severe hepatic impairment, and is prohibited for those with an active tuberculosis infection, directly constraining the eligible patient population.

Interactions with other Medicines and Products

Official regulatory information details clinically significant interactions primarily involving two main classes of substances, each requiring specific risk mitigation or timing adjustments.

---

Central Nervous System (CNS) Depressants

This drug has a documented pharmacodynamic interaction when combined with CNS depressants. These include opioid analgesics (such as morphine), sedatives, hypnotics, anxiolytics (like benzodiazepines), and alcohol. The combination results in an increased risk of severe, potentially life-threatening side effects, including profound sedation and respiratory depression. Regulatory agencies require close monitoring of patients receiving these concomitant medicines, particularly when therapy is initiated or when the dose of either medicine is increased, to manage the additive depressive effects.

---

Antacids Containing Aluminum and/or Magnesium

A pharmacokinetic interaction exists with antacids that contain aluminum hydroxide and/or magnesium hydroxide. When taken concurrently, these antacids are shown to reduce the amount of the drug absorbed into the bloodstream. To prevent this reduction in efficacy, official administration rules require that the dose of this medicine must be separated from the dose of the antacid by at least two hours.

Litai, which contains the lithium ion (Li^+), exhibits pharmacodynamic action through multiple intracellular and membrane-associated targets, primarily within the central nervous system. The cation functions as a non-competitive inhibitor of key enzymes in the phosphatidylinositol signaling pathway, including inositol monophosphatase (IMPase) and inositol polyphosphatase. This inhibition restricts the recycling of myo-inositol, reducing the synthesis of second messengers, specifically inositol triphosphate (IP3) and diacylglycerol (DAG), thereby modulating downstream calcium signaling and neuronal excitability.

Simultaneously, Li^+ acts as an inhibitor of glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase involved in regulating numerous cellular functions, including neuronal plasticity and gene transcription. The inhibition of GSK-3 affects the beta-catenin pathway, facilitating the nuclear translocation of beta-catenin and subsequent transcription of neurotrophic and cytoprotective proteins. Furthermore, Li^+ modulates neurotransmitter systems by altering presynaptic dopamine activity and postsynaptic G protein coupling. It is also shown to downregulate N-methyl-D-aspartate (NMDA) receptor expression and enhance glutamate reuptake, contributing to the overall modulation of excitatory neurotransmission.

How to Use Litai: Official Administration Guidelines

Litai is administered orally, typically as tablets, and must be taken according to the precise instructions provided by your healthcare provider. Adhering to the administration schedule and rules for dose modification is critical for safe use.

Dosing and Schedule

The recommended starting dose for Litai is 5 mg, taken by mouth twice daily. Doses should be taken approximately 12 hours apart, and may be administered with or without food.

Procedural Detail	Official Requirement
Route of Administration	Oral
Tablet Preparation	Swallow whole with water. Do not crush, split, or chew.
Missed Dose	If a dose is missed or if vomiting occurs, do not take an additional dose. Take the next prescribed dose at the usual scheduled time.

Dose Modification and Special Conditions

Your healthcare provider may adjust the dose of Litai based on individual safety and how well the treatment is tolerated. Specific dose reductions are required if you are taking certain co-administered drugs, such as strong CYP3A4/5 inhibitors, or if you have moderate hepatic impairment.

Litai must be withheld for at least 2 days prior to elective surgery. Following major surgery, treatment should not be resumed for at least 2 weeks, and only once adequate wound healing is achieved. The safety and effectiveness of Litai in pediatric patients has not been established.

Research Evidence / Overview of Studies for Litai

---

Evidence for use in Type 2 Diabetes Mellitus

Research related to Litai for use in conditions associated with systemic or functional imbalance, such as Type 2 Diabetes, was studied for its impact on key health measurements. The main research design was evaluated in short- to intermediate-term randomized controlled trials (RCTs). These studies research examined how blood sugar markers, like HbA1c, evolved in the observed populations, and also monitored body weight and metrics related to fat and cholesterol levels.

Studies monitored blood sugar markers, and findings describe patterns observed in which participants receiving the study intervention showed different measurements compared to the control group over the observed follow-up period. This research provides insight into short-term changes in these outcomes. However, long-term effects are not fully established regarding the maintenance of these measured changes beyond one year, and data for certain groups remain insufficient.

---

Evidence for use in Cardiovascular Risk Reduction

Research examining Litai and its association with major cardiovascular events was evaluated in large, long-term studies called Cardiovascular Outcome Trials (CVOTs). These trials research examined a specific group of high-risk adults with Type 2 Diabetes who already had existing heart or circulatory issues or multiple significant risk factors. The primary measurement monitored was a composite outcome that included events like heart attack, stroke, and cardiovascular death.

---

Evidence for use in Chronic Weight Management

Litai was studied for use in adults who are overweight or obese, in research exploring short-term and intermediate symptom changes. Studies monitored body weight, and findings describe patterns observed in which participants receiving the study intervention showed different body weight measurements compared to the control groups over the observed period. There is limited information for long-term outcomes regarding how well any observed weight change is maintained beyond two years.

---

What is Still Uncertain about Litai Research

While the research describes patterns related to outcomes in the studied populations, several areas of uncertainty remain. Certainty remains low for long-term changes in some aspects of use, as follow-up durations were limited in many studies. The existing research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Common questions about Litai (FAQ)

Q: What are the risks if I take Litai with alcohol?

Official product information states that taking Litai with central nervous system (CNS) depressants, which includes alcohol, can increase the risk of severe side effects. This combination is associated with an increased potential for severe side effects, including profound sedation (extreme drowsiness) and respiratory depression (slowed or shallow breathing).

---

Q: What specific kind of infections is Litai used to treat, according to its antibacterial activity?

Official product information indicates Litai may be used to treat serious infections caused by susceptible anaerobic bacteria, which are microorganisms that do not require oxygen to grow. It is also indicated for specific infections due to susceptible strains of streptococci, pneumococci, and staphylococci.

---

Q: Is Litai a bacteriostatic or bactericidal antibiotic?

Litai is generally classified as a bacteriostatic agent. This means it acts by limiting the growth of bacteria, rather than directly killing them.

---

Q: How long do I have to wait to resume Litai after major surgery?

According to official administration guidelines, Litai must be withheld for at least 2 days before any elective surgery. Following major surgery, treatment resumption is not recommended for at least 2 weeks and should only occur once adequate wound healing is confirmed by a healthcare professional.

---

Q: Is Litai a brand name or a generic name drug?

The active ingredient in Litai, Clindamycin, is the generic name for the substance. This medicine is often sold globally under a variety of different brand names.

---

Q: What is the shelf life/expiration date of Litai once I have opened the container?

The manufacturer-provided expiration date on the package applies to unopened containers. For forms that require mixing (such as reconstituted liquids), official labeling may specify a discard date for the unused portion, which is often around two weeks after mixing. It is important to follow the specific instructions provided on the product label.

---

Q: How should I store Litai at home?

Most forms of this drug should be stored at controlled room temperature, which is typically defined as 20^circ to 25 C (68^circ to 77 F). The medication is required to be kept in its original packaging and protected from excess moisture and light.

---

Q: Is Litai safe to use during pregnancy or while breastfeeding?

Official product information advises that during pregnancy, Litai should be used in the first trimester only if clearly needed. For breastfeeding, the drug is known to pass into human milk in small amounts, and use is generally advised against due to the potential for serious adverse effects, such as diarrhea or colitis, in the infant.

---

Q: What are the specific signs of Pseudomembranous Colitis I should watch for?

Regulatory warnings describe this condition as a severe adverse reaction that may be characterized by severe persistent diarrhea and severe abdominal cramps. The condition may also be associated with the passage of blood and mucus in the stool. These symptoms can occur during therapy or up to several weeks after stopping the drug.

Prescription medications like Litai must be stored according to the requirements specified on the product’s label to maintain their quality, strength, and purity. This typically requires storage at controlled room temperature or the specific temperature range stated in the product instructions. Drugs that are sensitive to light or moisture must be kept in their original, protective packaging. After reconstitution or first use, any stated in-use stability period must be strictly followed.

Disposal of Unused Medicine

To dispose of unused or expired Litai, follow any specific disposal instructions provided on the label or patient information leaflet. The best option is generally to use a drug take-back program or an authorized mail-back service. If these options are not readily available, and the drug is not on the specific government flush list, the medication should be mixed with an undesirable substance (such as dirt, used coffee grounds, or cat litter), placed in a sealed container, and thrown into the household trash. Do not flush the medicine down the toilet or sink unless the labeling explicitly directs it.